M&A WATCH- Our friends at the Egyptian American Enterprise Fund (EAEF) are reportedly planning to invest in Orchidia Pharma, sources close to the matter tell Al Borsa. While EAEF is hoping to acquire up to 100% of the company, it would settle on a majority stake of 55%, the sources told the newspaper, adding that due diligence is already underway ahead of presenting the company with a formal offer. Orchidia, which holds a 30% market share of the domestic eye drops market, is majority owned by its chairman Osama Abbas, who holds a 62% stake in the company. Investment firm Swicorp owns 38% of the company through its Intaj Capital II fund and had reportedly been looking to sell its stake. The newspaper also reports that Orchidia had been an acquisition target for Jordan’s Hikma last year. Acquisition talks failed on a buyer-seller price disconnect, as Hikma was offering c. EGP 400 mn against a demand of EGP 450 mn from shareholders.
More from Enterprise
The digital EGP won’t look different at checkout — but it will work nothing like InstaPay
Every instant payment today depends on your bank or telco.…
Granite is about to test whether Egypt’s funds still need administrators
The asset manager and blockchain builder Tarmiiz have entered the…
Egypt is fixing how deals get executed, but what pushes investors offshore runs deeper than the reforms on the table
Investment Ministry and a Senate committee are both moving to…
Egyptian-UK fintech Zeal raises USD 10 mn to back expansion plans
The London-based, Egyptian-founded fintech is preparing to activate its loyalty…